LPCN Lipocine Inc.
NEUTRAL
Impact: 4/10
8-K
8-K context-dependent: Items 8.01
Latest settled — T+5d
LPCN ▼ -3.95% at T+5d
NEUTRAL call ✗ call lost -3.95% · α vs SPY -4.42% · entry $2.28 → $2.19
Last close $2.26 (close Jun 12) · -0.88% from $2.28 entry
T+1d
-0.88%
call -0.88% · α -1.43%
$2.26
settled 19d ago
T+5d
-3.95%
call -3.95% · α -4.42%
$2.19
settled 13d ago
T+20d
—
call — · α —
—
in 9d
T+60d
—
call — · α —
—
in 2mo
Price Chart
Loading chart...
Executive Summary
Lipocine announced the presentation of Phase 3 clinical data for LPCN 1154 (oral brexanolone) for postpartum depression at the ASCP Annual Meeting on May 26, 2026. The filing includes the presentation and poster as exhibits, but no specific efficacy or safety results are discussed in the 8-K.
Actionable Insight
Monitor market reaction to the Phase 3 data presentation. If data is positive, LPCN 1154 could become a significant asset; if negative, the stock may decline. Further details are in the exhibits.
Key Facts
- Lipocine presented Phase 3 clinical data for LPCN 1154 (oral brexanolone) for postpartum depression at ASCP Annual Meeting on May 26, 2026
- Presentation and poster are furnished as Exhibit 99.1 and 99.2
Financial Impact
No financial figures reported
Risk Factors
- Phase 3 data may not meet efficacy endpoints
- Competitive landscape includes other PPD treatments like Zulresso (brexanolone) and zuranolone
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025270 |
| Document: 0001493152-26-025270-index-headers.html | 0001493152-26-025270 |
| Document: 0001493152-26-025270-index.html | 0001493152-26-025270 |
| Document: 0001493152-26-025270.txt | 0001493152-26-025270 |
9 reports for LPCN
100%
Hit rate
best @ T+20▲ +9.09%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
8-K
| $2.21 $2.05 | ▼ −7.24% | ▼ −4.64% | $2.26 (+2.26%) |
|
May 26, 2026
19d ago
|
8-K
| $2.28 $2.26 | ▼ −0.88% | ▼ −1.43% | $2.26 (−0.88%) |
|
May 19, 2026
26d ago
|
8-K
| $2.20 $2.24 | ▲ +1.82% | ▲ +0.78% | $2.26 (+2.73%) |
|
May 18, 2026
27d ago
|
8-K
| $2.21 $2.20 | ▼ −0.45% | ▲ +0.20% | $2.26 (+2.26%) |
|
May 7, 2026
5w ago
|
8-K
| $2.39 $2.37 | ▲ +0.84% | ▲ +1.67% | $2.26 (+5.44%) |
|
Apr 21, 2026
7w ago
|
8-K
| $2.42 $2.35 | ▲ +2.89% | ▲ +2.50% | $2.26 (+6.61%) |
|
Apr 2, 2026
10w ago
|
8-K
| $2.05 $1.94 | ▼ −5.37% | ▼ −5.84% | $2.26 (+10.24%) |
|
Apr 2, 2026
10w ago
|
8-K
| $2.05 $1.94 | ▲ +5.37% | ▲ +5.84% | $2.26 (−10.24%) |
|
Mar 4, 2026
14w ago
|
8-K
| $8.19 $8.13 | ▼ −0.73% | ▲ +0.58% | $2.26 (−72.41%) |
Showing 9 of 9
US Market Status
Market Closed — Opens in 2h 52m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access